Exploration of Targeted Anti-tumor Therapy

Table 2. Systemic therapy prior to TC for 32 patients.

Systemic therapy	n (%) or median (range)
Prior frontline systemic therapy	31 (97%)
Platinum-based chemotherapy	12 (38%)
Non-platinum-based chemotherapy	1 (3%)
ICI monotherapy	14 (44%)
ICI-based clinical trial	1 (3%)
Erdafitinib	1 (3%)
Enfortumab vedotin and pembrolizumab	2 (6%)
ICI prior to starting TC	32 (100%)
Pembrolizumab	25 (78%)
Avelumab	3 (9%)
Nivolumab	2 (6%)
Atezolizumab	2 (6%)
Median number of ICI cycles (range)	6 (1–22)
Median weeks of ICI (range)	16 (3–225)
Number of lines of systemic therapy in the metastatic setting prior to starting TC
0	1 (3%)*
1	19 (59%)
2	11 (34%)
3+	1 (3%)

Return to article view

TC: paclitaxel and carboplatin; ICI: immune checkpoint inhibitor. *: This patient received adjuvant nivolumab, and therefore TC was a first-line metastatic regimen.

Declarations

Author contributions

AJ: Writing—review & editing, Writing—original draft, Visualization, Investigation, Formal analysis, Data curation, Conceptualization. MM: Writing—review & editing, Investigation, Data curation. MS: Writing—review & editing, Investigation. TB: Writing—review & editing, Investigation. AS: Writing—review & editing, Investigation. EIH: Writing—review & editing, Investigation. BAC: Writing—review & editing, Investigation. JJO: Writing—review & editing, Investigation. JFQ: Writing—review & editing, Investigation. DSC: Writing—review & editing, Visualization, Investigation, Formal analysis, Data curation, Conceptualization, Supervision. LCP: Writing—review & editing, Writing—original draft, Visualization, Investigation, Formal analysis, Data curation, Conceptualization, Supervision. All authors read and approved the submitted version.

Conflicts of interest

AJ has received personal fees from RealTimeCase, honoraria from MJH Life Sciences and Curio Science, and travel funds from MECC Inc and the Binaytara Foundation. JJO receives research support from the Prostate Cancer Foundation (YIA), Department of Defense, and National Cancer Institute (K12 CA90628-23), has current clinical trial support from Janux Therapeutics, and has received support from NaNotics, NEXUS Global, Genentech, Johnson & Johnson, and Partner Therapeutics, and reports support and/or research and consulting support from the Prostate Cancer Foundation, NaNotics, Nexus Global, Genentech, and Partner Therapeutics. All other authors report no relevant conflicts of interest.

Ethical approval

This study was approved by the Mayo IRB#: 20-011547.

Consent to participate

This study was deemed exempt by the Mayo Clinic Institutional Review Board (IRB#: 20-011547), so individual patient consent was not required.

Consent to publication

This study was deemed exempt by the Mayo Clinic Institutional Review Board (IRB#: 20-011547), so individual patient consent was not required.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Funding

Not applicable.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Jang A, Adler DM, Rauterkus GP, Bilen MA, Barata PC. Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going? Cancers. 2021;13:5065. [DOI] [PubMed] [PMC]

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017;376:1015–26. [DOI] [PubMed] [PMC]

Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483–92. [DOI] [PubMed]

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383:1218–30. [DOI] [PubMed]

Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390:875–88. [DOI] [PubMed]

van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2023;389:1778–89. [DOI] [PubMed] [PMC]

Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021;384:2102–14. [DOI] [PubMed] [PMC]

Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, et al. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med. 2024;391:1773–86. [DOI] [PubMed]

Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, et al. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2023;389:1961–71. [DOI] [PubMed]

10.

Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A, et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol. 2024;42:47–58. [DOI] [PubMed] [PMC]

11.

Vaughn D. Paclitaxel and carboplatin in bladder cancer. Eur J Cancer. 2000;36:7–12. [DOI] [PubMed]

12.

Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, et al. Phase II trial of carboplatin and paclitaxel in cisplatin‐pretreated advanced transitional cell carcinoma. Cancer. 2005;104:1627–32. [DOI] [PubMed]

13.

Childs DS, Quevedo JF, Costello BA, Pagliaro LC. Chemoimmunotherapy after progression on single-agent pembrolizumab for metastatic urothelial carcinoma: a case series. Anti-Cancer Drugs. 2021;32:986–90. [DOI]

14.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. [DOI]

15.

Furubayashi N, Hori Y, Morokuma F, Tomoda T, Negishi T, Inoue T, et al. Paclitaxel and carboplatin chemotherapy after platinumbased chemotherapy and pembrolizumab for metastatic urothelial carcinoma. Mol Clin Oncol. 2021;14:91. [DOI] [PubMed] [PMC]

16.

Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, et al. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med. 2016;374:738–48. [DOI] [PubMed] [PMC]

17.

Marchetti C, De Felice F, Musella A, Palaia I, Monti M, Musio D, et al. Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis. Oncotarget. 2016;7:58709–15. [DOI] [PubMed] [PMC]

18.

Safra T, Waissengrin B, Levy T, Leidner E, Merose R, Matceyevsky D, et al. Weekly Carboplatin and Paclitaxel: A Retrospective Comparison with the Three-Weekly Schedule in First-Line Treatment of Ovarian Cancer. Oncologist. 2020;26:30–9. [DOI]

19.

Dessai SB, Chakraborty S, Babu TV, Nayanar S, Bhattacharjee A, Jones J, et al. Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin. South Asian J Cancer. 2016;5:63–6. [DOI] [PubMed] [PMC]

20.

Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 2019;30:219–35. [DOI] [PubMed]

21.

Dwary AD, Master S, Patel A, Cole C, Mansour R, Mills G, et al. Excellent response to chemotherapy post immunotherapy. Oncotarget. 2017;8:91795–802. [DOI] [PubMed] [PMC]

22.

Vulsteke C, Adra N, Danchaivijitr P, Sabadash M, Rodriguez-Vida A, Zhang Z, et al. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med. 2026;394:1257–69. [DOI] [PubMed]

23.

Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu T, Chatzkel J, et al. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. N Engl J Med. 2026;395:338–48. [DOI] [PubMed]